Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
9 participants
INTERVENTIONAL
2017-07-24
2019-04-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Nitric Oxide (NO) has been shown to play a critical role in various biological functions. In the airways, NO is considered to play a key role in the innate immune system in which the first-line of host defense against microbes is built.
In vitro studies suggested that NO, in part per million (ppm) concentrations, possesses anti-microbial activity against a wide variety of phyla including fungi, and antibiotic-resistance bacteria.
In this study the investigators wish to evaluate the efficacy, safety and tolerability of 160 ppm Nitric Oxide intermittently delivered via inhalation to subjects infected with Non-tuberculosis mycobacteria (NTM), specifically with MABSC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection
NCT04290858
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
NCT04305457
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)
NCT06663176
Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis
NCT02714283
Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease
NCT05192057
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nitric Oxide treatment
Nitric Oxide
Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nitric Oxide
Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of pulmonary non-tuberculosis mycobacterial lung disease in accordance with the 2007 ATS/IDSA criteria with evidence of nodular bronchiectasis and/or cavitary disease by chest computed tomography (CT) and by culture.
3. History of at least 6 months chronic infection with Mycobacterium abscessus.
4. Mycobacterium abscessus positive sputum sample at screening or prior to screening.
5. Receiving ATS/IDSA guidelines-based treatment regimen defined as: adherent to a multi-drug regimen for at least 6 months prior to screening with persistently positive mycobacterial abscessus cultures.
6. FEV1 ≥ 30% at screening as well as baseline.
7. Ability to produce sputum or be willing to undergo an induction of sputum for clinical evaluation.
8. Life expectancy ≥1 year
9. Ability to perform 6MWT, but not to exceed a distance of 700 meters during screening.
10. Ability to understand and comply with study requirements.
11. Approved and signed informed consent by subject and/or by parent/legal guardian (depending on subject's age).
Exclusion Criteria
2. Subjects diagnosed with methemoglobinemia, immunodeficiency, heart disease, pulmonary hypertension and/or high blood pressure.
3. Use of an investigational drug during the last 30 days prior enrollment and/or the subject is expected to participate in a new study within five months from enrollment to this study.
4. History of frequent epistaxis (\>1 episode/month).
5. Significant hemoptysis during the last 30 days prior to enrolment (\>30 Ml of blood in a 24-hour period).
6. Methemoglobin level \>2% at screening.
7. Patients on inconsistant dosage of systemic steroids (any formulation) 30 days prior to enrolment.
8. History of illicit drug or medication abuse within 1 year of screening.
9. History of lung transplantation.
10. History of daily, continuous oxygen supplementation.
11. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data.
12. Pulmonary tuberculosis requiring treatment or treated within 2 years prior to screening.
13. Any change in chronic NTM multi-drug regimen within 28 days prior to study day 1.
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beyond Air Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rambam Medical Center
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AIT_ CP_ CFNTM_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.